

# **Meningococcal Conjugate Vaccine Supply & Demand Public Sector**

**Advisory Committee on Immunization Practices**

**June 27, 2007**

**Gregory S. Wallace , M.D., M.S., M.P.H.**

**Chief, Vaccine Supply and Assurance Branch**

**Immunization Services Division**

**National Center for Immunization and Respiratory Diseases**

**Centers for Disease Control and Prevention**



# Menactra Milestones

- **FDA Approval – Jan 14, 2005**
- **ACIP/VFC Approval – Feb 10, 2005**
- **CDC Contract – Apr 1, 2005**
- **MMWR Publication – May 27, 2005**
- **Defer 11-12 year old dose – May 19, 2006**
- **End 11-12 deferral – Nov 3, 2006**




# Supply & Demand & Recommendations

- Recommendation for 2 cohorts plus 18 year olds living in dorms recognizing supply may be limited
- Allocation to public sector based on VFC populations
- 18 year old demand from previous MPSV4 recommendation
- Real demand for new vaccine unpredictable



# Implementation of MCV4



# Public Sector Demand

Vaccine	2005	2006	2007 (through 6/15/2007)
MCV4	1.4 of 3.1 (46%)	1.7 of 4.2 (40%)	0.9 of ??
Tdap	1.1 of 4.7 (24%)	3.7 of 9.2 (41%)	1.0 of ??
HPV	---	1.1 of 2.2 (50%)	2.1 of ??

Tdap available 4 months in public sector in 2005, 6 months in private sector

HPV available 2 months in public sector in 2006, 6 months in private sector



# **Public Sector Response to 11-12 year old deferral**

- **Difficult to reach public sector adolescents beyond 11-12 years**
- **Public sector providers don't see majority of 18 year olds where demand is highest**
- **Drop in doses used resulting in risk of expiration of vaccine on-hand**
- **Demand has not picked up since removal of deferral**



# Summary

- **Doses available increasing, use in the public sector is not, resulting in expiration of vaccine risk**
- **Current recommendations can result in missed opportunities for protection**

